Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from NuGen Medical Devices Inc ( (TSE:NGMD) ) is now available.
NuGen Medical Devices Inc. has launched a dedicated French-language e-commerce platform for its needle-free insulin-delivery device, InsuJet™, in collaboration with Sol-Millennium France. This initiative aims to address the growing diabetes challenge in France, where 4.33 million people were living with diabetes in 2022. By eliminating needle anxiety, InsuJet™ promotes earlier insulin use, potentially reducing healthcare costs and improving patient outcomes. The device, which has been well-received by the healthcare community, offers benefits such as faster insulin absorption and higher patient satisfaction, aligning with France’s demand for safer and more economical diabetes care.
More about NuGen Medical Devices Inc
NuGen Medical Devices Inc. is a leader in needle-free subcutaneous drug-delivery technology. The company develops next-generation needle-free devices, with its flagship product, the InsuJet™ system, designed to improve the lives of millions of people with diabetes worldwide. The InsuJet™ system is approved in 42 countries.
Average Trading Volume: 149,167
Technical Sentiment Signal: Sell
Current Market Cap: C$12.49M
Find detailed analytics on NGMD stock on TipRanks’ Stock Analysis page.